{"filing":{"accession_number":"0001213900-26-090183","cik":"0001860657","ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"ea0302157-8k_allarity.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026090183/ea0302157-8k_allarity.htm"},"events":[{"id":27983,"run_id":25562,"accession_number":"0001213900-26-090183","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses Allarity Therapeutics' financial results for the second quarter ended June 30, 2026, via a press release dated August 14, 2026. Item 2.02 explicitly covers \"Results of Operations and Financial Condition,\" and the press release reports Q2 2026 financial metrics including cash position ($26.9 million), R\u0026D expenses ($1.3 million), G\u0026A expenses ($1.3 million), and comprehensive loss ($3.7 million), alongside operational highlights such as completion of Phase 3 manufacturing, patent grant, and CLIA certification. This is a standard quarterly earnings disclosure.","company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29732,"accession_number":"0001213900-26-090183","item_number":"2.02","item_title":"Results","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Allarity Therapeutics' financial results for the second quarter ended June 30, 2026, via a press release dated August 14, 2026. Item 2.02 explicitly covers \"Results of Operations and Financial Condition,\" and the press release reports Q2 2026 financial metrics including cash position ($26.9 million), R\u0026D expenses ($1.3 million), G\u0026A expenses ($1.3 million), and comprehensive loss ($3.7 million), alongside operational highlights such as completion of Phase 3 manufacturing, patent grant, and CLIA certification. This is a standard quarterly earnings disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:45:04.984586+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29732,"accession_number":"0001213900-26-090183","item_number":"2.02","item_title":"Results","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Allarity Therapeutics' financial results for the second quarter ended June 30, 2026, via a press release dated August 14, 2026. Item 2.02 explicitly covers \"Results of Operations and Financial Condition,\" and the press release reports Q2 2026 financial metrics including cash position ($26.9 million), R\u0026D expenses ($1.3 million), G\u0026A expenses ($1.3 million), and comprehensive loss ($3.7 million), alongside operational highlights such as completion of Phase 3 manufacturing, patent grant, and CLIA certification. This is a standard quarterly earnings disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:45:04.984586+00:00","company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","filing_date":"2026-08-14"}]}